Our pilot studies have newly identified that BiologicMate® can also predict the efficacy of etanercept (ETN), in addition to the efficacy of infliximab (IFX), adalimumab (ADA), tocilizumab (TCZ), and abatacept (ABA).
Baseline ADAMTS5 mRNA level in RA patients who were responders to etanercept or infliximab was lower compared with non-responders. On the other hand, baseline ADAMTS5 in patients who were responders to adalimumab, tocilizumab, or abatacept was higher than non-responders.
Cut-off value of the baseline ADAMTS5 mRNA to predict the response against each biologic was determined using the ROC curves.
DAS28 of Low-ADAMTS5 group patients was significantly lower than High-ADAMTS5 group patients after the treatment with etanercept or infliximab. On the other hand, DAS28 of High-ADAMTS5 group patients was significantly lower than Low-ADAMTS5 group patients after the treatment with adalimumab, tocilizumab, or abatacept.